Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insight Pharmaceuticals has taken over vaginal antifungal drug Monistat North American brand portfolio from McNEIL-PPC to strengthen its family of over-the-counter (OTC) women's health and personal care products.
Subscribe to our email newsletter
Following the acquisition, Monistat will continue to be available through existing retail channels and will be marketed under Insight Pharmaceuticals growing portfolio of products.
Insight Pharma CEO Gary Downing said this acquisition, along with e.p.t, has increased their revenues by nearly four times in the last 12 months.
"Additionally, as part of the e.p.t transaction, Insight acquired the Uristat urinary pain treatment brand and is preparing to re-launch the brand," Downing said.